Some tips to help get started:
There are 386 active trials for advanced/metastatic non-small cell lung cancer. Click on a trial to see more information.
386 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial compares sigvotatug vedotin, an antibody-drug conjugate targeting integrin beta-6, against docetaxel in previously treated adult patients with locally advanced, unresectable or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior platinum-based chemotherapy and anti-PD-(L)1 agents.
ClinicalTrials.gov ID: NCT06012435
HealthScout AI summary: This trial involves adult patients with metastatic squamous non-small cell lung cancer who have not previously received systemic treatment, comparing the efficacy and safety of ivonescimab, a novel antibody potentially targeting multiple pathways, combined with chemotherapy, against pembrolizumab, a PD-1 inhibitor, combined with chemotherapy.
ClinicalTrials.gov ID: NCT05899608
HealthScout AI summary: This trial evaluates divarasib, a novel oral KRAS G12C inhibitor, against sotorasib and adagrasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who have progressed after 1-3 prior treatments, aiming to assess efficacy and safety among these therapies.
ClinicalTrials.gov ID: NCT06497556
HealthScout AI summary: This trial compares DZD9008, an investigational EGFR tyrosine kinase inhibitor targeting exon 20 insertion mutations, to standard platinum-based chemotherapy in treatment-naïve adult patients with locally advanced or metastatic non-squamous NSCLC harboring EGFR exon 20 insertion mutations.
ClinicalTrials.gov ID: NCT05668988
HealthScout AI summary: This trial targets participants with metastatic non-small cell lung cancer (NSCLC) with PD-L1 expression of ≥50%, comparing overall survival with the combination of sacituzumab tirumotecan, a TROP2-targeting antibody-drug conjugate, and pembrolizumab, to pembrolizumab alone.
ClinicalTrials.gov ID: NCT06170788
HealthScout AI summary: This trial involves patients aged 18 or older with locally advanced or metastatic nonsquamous NSCLC harboring EGFR exon 20 insertion mutations, evaluating the efficacy and safety of the investigational drug zipalertinib, an oral tyrosine kinase inhibitor targeting these mutations, in combination with standard chemotherapy versus chemotherapy alone.
ClinicalTrials.gov ID: NCT05973773
HealthScout AI summary: This trial targets adult patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harboring HER2 tyrosine kinase domain mutations, comparing the investigational drug zongertinib, a HER2-targeted tyrosine kinase inhibitor, against the standard treatment of pembrolizumab combined with platinum-pemetrexed chemotherapy as first-line therapy.
ClinicalTrials.gov ID: NCT06151574
HealthScout AI summary: This study involves adult patients with advanced or metastatic NSCLC without EGFR, ALK, or ROS1 mutations that have progressed after front-line ICI-based maintenance therapy, comparing the safety and efficacy of the oncolytic vaccinia virus Olvi-Vec with platinum-doublet chemotherapy and a chosen ICI versus docetaxel.
ClinicalTrials.gov ID: NCT06463665
HealthScout AI summary: This trial involves patients with advanced LKB1-mutant non-small cell lung cancer refractory to prior anti-PD1 treatment, including a cohort with KRAS mutations, who will receive a combination of defactinib (a focal adhesion kinase inhibitor), avutometinib (a dual RAF/MEK inhibitor), and nivolumab (a PD-1 blocking antibody).
ClinicalTrials.gov ID: NCT06495125
HealthScout AI summary: This trial involves patients with stage IV KRAS G12C-mutant metastatic NSCLC and PD-L1 TPS ≥50%, comparing the combination of MK-1084, a selective KRAS G12C-GDP inhibitor, with pembrolizumab against pembrolizumab plus a placebo as first-line treatment.
ClinicalTrials.gov ID: NCT06345729